A Detour for Prostate Cancer Cell Survival and Growth
Second generation AR antagonists, abiraterone and enzalutamide, induce aberrant HGF/MET and Wnt pathways leading to increased XPO1 expression and ribosomal biosynthesis in double-null prostate cancer (DNPC). However, treatment with XPO1 and ribosomal inhibitors showed an improved antitumor response.